---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-058659"
form_type: "8-K/A"
ticker: "ROIV"
cik: "0001635088"
company_name: "Roivant Sciences Ltd."
filed_at: "2023-12-20T23:59:59+00:00"
generated_at: "2026-06-07T09:51:49.298912+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Roivant files pro forma financials for $7.1B Telavant sale to Roche; gain of $5.3B

## Summary
- Roivant sold its 75% stake in Telavant to Roche for ~$7.1B cash plus $150M milestone for Phase 3 trial initiation.
- Pro forma cash and cash equivalents at Sep 30, 2023: $6.6B, up from $1.4B historical.
- Pro forma net income attributable to Roivant for FY Mar 2023: $4.3B vs historical net loss of $1.1B.
- Pro forma net loss for H1 Sep 2023: $552M vs historical loss of $596M; reduction from eliminated Telavant R&D.
- Transaction accounted for as sale of nonfinancial assets; $5.3B gain recognized.

## SEC filing metadata
- accession: 0001140361-23-058659
- form_type: 8-K/A
- ticker: ROIV
- cik: 0001635088
- company_name: Roivant Sciences Ltd.
- filed_at: 2023-12-20T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1635088/000114036123058659/0001140361-23-058659-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1635088/000114036123058659/ef20017039_8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-058659
- JSON: https://secwatch.observer/filing/0001140361-23-058659.json
- Plain text: https://secwatch.observer/filing/0001140361-23-058659.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.